Download presentation
Presentation is loading. Please wait.
Published byสมบูรณ์ สมิท Modified over 5 years ago
1
Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders Lauri M. Burroughs, Akiko Shimamura, Julie-An Talano, Jennifer A. Domm, Kelsey K. Baker, Colleen Delaney, Haydar Frangoul, David A. Margolis, K. Scott Baker, Eneida R. Nemecek, Amy E. Geddis, Brenda M. Sandmaier, H. Joachim Deeg, Rainer Storb, Ann E. Woolfrey Biology of Blood and Marrow Transplantation Volume 23, Issue 10, Pages (October 2017) DOI: /j.bbmt Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions
2
Figure 1 CD3+ and CD33+ donor chimerism in 14 patients conditioned with treosulfan-based conditioning. Shown are the percent donor chimerism of sorted peripheral blood CD3+ (A) and CD33+ (B) subsets according to day after transplant. Overlapping points at days +28, +80, +180, years, and at 100% chimerism, are jittered slightly to improve visibility. Biology of Blood and Marrow Transplantation , DOI: ( /j.bbmt ) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions
3
Figure 2 Disease-free survival. Shown is the Kaplan-Meier estimate of disease-free survival for 14 patients with bone marrow failure disorders who received treosulfan-based conditioning. Biology of Blood and Marrow Transplantation , DOI: ( /j.bbmt ) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.